Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last --
Change Today 0.00 / 0.00%
Volume 0.0
1530 On Other Exchanges
Symbol
Exchange
1530 is not on other exchanges.
All times are local (Market data is delayed by at least 15 minutes).

3sbio inc (1530) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
0.0
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for 3SBIO INC (1530)

3sbio inc (1530) Related Bloomberg News

View More Bloomberg News

3sbio inc (1530) Related Businessweek News

No Related Businessweek News Found

3sbio inc (1530) Details

3SBio Inc., a biotechnology company, develops, manufactures, markets, and sells biopharmaceuticals in China. Its principal products include EPIAO, an injectable recombinant human erythropoietin for anemia associated with chronic kidney disease (CKD), and chemotherapy-induced anemia (CIA), as well as to reduce allogeneic blood transfusion in surgery patients; and TPIAO, a recombinant human thrombopoietin for chemotherapy-induced thrombocytopenia and immune thrombocytopenia. The company also offers IV Iron Sucrose, an iron sucrose injection product for iron deficiency anemia; SEPO, an injectable product for anemia associated with CKD, and CIA; and Sparin, an injectable low-molecular-weight heparin calcium product for prophylaxis and vein thrombosis, and to prevent clotting during hemodialysis. In addition, it provides Intefen, a recombinant human interferon alpha-2a product for the treatment of malignancies of the lymphatic or hematopoietic system, and viral infectious diseases; and Inleusin, a recombinant human interleukin 2 product for renal cell carcinoma, melanoma, thoracic fluid build-up caused by cancer, and tuberculosis; and Gan Xin, a metadoxine drug for alcoholic liver disease. Further, the company offers aseptic and terminally sterilized, and biological injectable products in various formats, such as pre-filled syringes, lyophilized vials, liquid vials, and ampoules, as well as helps customers in development process for the registration of new or generic drugs. Additionally, it distributes anti-cancer drugs, such as docetaxel, anastrozole, and azasetron. 3SBio Inc. is also developing various product candidates in the nephrology, oncology, auto-immune diseases, and other areas. The company sells its products through in-house sales and marketing team, distributors, and third-party promoters to hospitals and medical institutions. 3SBio Inc. was incorporated in 2006 and is headquartered in Shenyang, China. 3SBio Inc. is a subsidiary of Decade Sunshine Limited.

1,352 Employees
Last Reported Date: 06/1/15
Founded in 2006

3sbio inc (1530) Top Compensated Officers

Co Founder, Chairman, Chief Executive Officer...
Total Annual Compensation: CNY912.0K
Chief Financial Officer, Executive Vice Presi...
Total Annual Compensation: CNY1.0M
Senior Vice President and Executive Director
Total Annual Compensation: CNY565.0K
Vice President and Executive Director
Total Annual Compensation: CNY40.0K
Compensation as of Fiscal Year 2014.

3sbio inc (1530) Key Developments

3SBio Seeks Acquisitions

3SBio Inc. filed an IPO in the amount of HKD 5.5 billion. It will use the proceeds to fund acquisitions and recruit staff to help it grab a bigger piece of the booming Chinese drug market.

3SBIO Launches IPO

3SBIO Inc. launches an IPO of HKD 712 million IPO in Hong Kong to fund acquisitions and recruit staff to help it grab a bigger piece of the booming Chinese drug market. 3SBIO plans to use 45%of the IPO proceeds to expand its portfolio of drugs through acquisitions, 15% to hire more sales staff and open offices around China, and another 15% for new production lines. The remainder would be spent on research and development and working capital.

3SBio Signs Exclusive Patent License Agreement for DIG-KT With PharmAbcine, Inc

3SBio Inc. announced that it has entered into an exclusive licensing deal with PharmAbcine Inc. for the development, manufacturing and marketing of DIG-KT, a bi-specific monoclonal antibody (mAb) targeting both VEGFR2/KDR and Tie-2 pathways for cancer in the territory of Greater China (including mainland China, Taiwan, Hong Kong and Macau) and Korea.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
1530:HK $9.02 HKD -0.08

1530 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Kirin Holdings Co Ltd ¥1,856 JPY 0.00
Roche Holding AG SFr.276.70 CHF +2.80
View Industry Companies
 

Industry Analysis

1530

Industry Average

Valuation 1530 Industry Range
Price/Earnings 0.0x
Price/Sales 0.0x
Price/Book 0.0x
Price/Cash Flow 8.3x
TEV/Sales 1.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact 3SBIO INC, please visit www.3sbio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.